138199-71-0

138199-71-0 structure

Name: Levofloxacin hydrate
Chemical Name: Levofloxacin Hemihydrate
CAS Number: 138199-71-0
Molecular Formula: C₁₈H₂₀FN₃O_4.0.5H₂O
Molecular Weight: 370.38
Catalog: API Synthetic anti-infective drugs Quinolone
Create Date: 2018-02-07 08:00:00
Modify Date: 2024-01-02 15:39:59
Levofloxacin hydrate is an antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.Target: AntibacterialLevofloxacin reduced bacterial load compared with placebo by 4.9-fold (95% confidence interval, 1.4-25.7; P=0.02) at day 7 but had no effect at any point on any marker of neutrophilic airway inflammation. In patients with a baseline bacterial load of more than 10(6) cfu/mL, levofloxacin treatment was associated with a 26.5% (95% confidence interval, 1.8%-51.3%; P=0.04) greater reduction in the percentage neutrophil count compared with placebo at day 7 [1]. Levofloxacin was found to significantly improve the clinical and microbiological parameters in CP individuals [2]. A 30-day course of levofloxacin does not significantly improve BK viral load reduction or allograft function when used in addition to overall reduction of immunosuppression [3].

Name	Levofloxacin Hemihydrate
Synonyms	Levofloxacin 7H-1,4-Oxazino[2,3,4-ij]quinoline-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (3S)-, hydrate (1:1) (3S)-9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid hydrate (1:1) MFCD03265511 Levofloxacin hemihydrate (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid hydrate (2:1) Levofloxacin hydrate

Description	Levofloxacin hydrate is an antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.Target: AntibacterialLevofloxacin reduced bacterial load compared with placebo by 4.9-fold (95% confidence interval, 1.4-25.7; P=0.02) at day 7 but had no effect at any point on any marker of neutrophilic airway inflammation. In patients with a baseline bacterial load of more than 10(6) cfu/mL, levofloxacin treatment was associated with a 26.5% (95% confidence interval, 1.8%-51.3%; P=0.04) greater reduction in the percentage neutrophil count compared with placebo at day 7 [1]. Levofloxacin was found to significantly improve the clinical and microbiological parameters in CP individuals [2]. A 30-day course of levofloxacin does not significantly improve BK viral load reduction or allograft function when used in addition to overall reduction of immunosuppression [3].
Related Catalog	Signaling Pathways >> Anti-infection >> Bacterial Research Areas >> Infection
References	[1]. Siva, R., et al., Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis, 2014. 9: p. 179-86. [2]. Pradeep, A.R., et al., Clinical and microbiological effects of levofloxacin in the treatment of chronic periodontitis: a randomized, placebo-controlled clinical trial. J Investig Clin Dent, 2014. [3]. Lee, B.T., et al., Efficacy of Levofloxacin in the Treatment of BK Viremia: A Multicenter, Double-Blinded, Randomized, Placebo-Controlled Trial. Clin J Am Soc Nephrol, 2014.

Density	1.48g/cm3
Boiling Point	571.5ºC at 760mmHg
Melting Point	214-216°C
Molecular Formula	C₁₈H₂₀FN₃O_4.0.5H₂O
Molecular Weight	370.38
PSA	84.24000
LogP	1.48260
Vapour Pressure	6.7E-14mmHg at 25°C
Storage condition	-20°C Freezer

Symbol	GHS07, GHS08
Signal Word	Danger
Hazard Statements	H302-H317-H334-H361d-H362
Precautionary Statements	P261-P263-P280-P342 + P311
Hazard Codes	N
Risk Phrases	50/53
Safety Phrases	S24/25
RIDADR	NONH for all modes of transport

109-01-3

100986-89-8

138199-71-0

Literature: US2003/130507 A1, ;

Precursor 2
109-01-3 100986-89-8
DownStream 0

138199-71-0	138199-72-1
1036016-10-0	117678-37-2
2268802-22-6	872606-49-0
2206135-16-0	138998-47-7
100986-89-8	177325-13-2